Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +4.03% 64.50p 63.00p 66.00p 65.50p 62.00p 62.00p 385,645 12:56:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.3 -1.5 1.7 38.6 50.66

Optibiotix H. (OPTI) Latest News

More Optibiotix H. News
Optibiotix H. Takeover Rumours

Optibiotix H. (OPTI) Share Charts

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart

Intraday Optibiotix H. Chart

Intraday Optibiotix H. Chart

Optibiotix H. (OPTI) Discussions and Chat

Optibiotix H. (OPTI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Optibiotix H. trades in real-time

Optibiotix H. (OPTI) Top Chat Posts

DateSubject
20/8/2017
09:20
Optibiotix H. Daily Update: Optibiotix H. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix H. was 62p.
Optibiotix H. has a 4 week average price of 54p and a 12 week average price of 54p.
The 1 year high share price is 89.50p while the 1 year low share price is currently 54p.
There are currently 78,543,318 shares in issue and the average daily traded volume is 405,061 shares. The market capitalisation of Optibiotix H. is £50,660,440.11.
17/8/2017
08:57
joyjoy13: OptiBiotix Health PLC Q&A with CEO Stephen O’Hara (LON:OPTI) Posted by: Amilia Stone 17th August 2017 OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the recent share price movement, their deal pipeline, the 39 potential RNS’s that could be announced in the following months & what this all means for investors Q1: Just recently, there’s been a fall in OptiBiotix Health’s share price, how would you explain the share price performance? A1: There has been some volatility in the share price, the first thing I wanted to do was to reassure investors that there’s nothing wrong. If you look back at where we are now to where we were say 12 months or so ago, the share price was higher 12 months or so ago but undoubtedly, we’re in a stronger position today than we were when the share price was trading at 80p. Even more importantly, if we look towards the future, there are a lot more opportunities we are progressing which are at a later stage, we touched on in previous RNS’s, and are entering the commercialisation phase. We do recognise there is uncertainty in small caps in general, and that’s across the board, and we do have a large retail investor base so we will get peaks and troughs, some shareholders just take profit and there’s also some uncertainty in the external environment which means that some retail investors start to take a shorter view. I would say that if you look at where we are with the company, we’ve just entered a commercialisation and I believe this next stage of growth, there’s a potential for share growth which will come when we gain commercial traction with our products. Based on the high level of interest and lots of ongoing discussions, this look extremely promising and investors who attended my investor share results presentation earlier on in the year will recognise we have a structured plan and that’s the reason we appointed a new Commercial Director, Per Rehné and a new Sales Director in January 2017. They joined us at the end of March and as planned, we launched products in May and as I reported in previous RNS’s, there’s been a lot of interest, extensive interest, from our launch of Vitafoods in the middle of May, we’ve been working hard to close out deals from those discussions. We have closed out 2 deals, one with HLH and one with Pharmabiota, both these are privately-owned pharmaceutical companies so they are far quicker in decision making. As people are also aware, HLH they had an initial order of 100,000 and last week they ordered another 200,000 units so you can see that it’s not just signing deals, HLH for example signed a deal, put the products on the market and now re-ordered twice the number of units they ordered initially. We have a number of agreements in our pipeline, 4 private companies like HLH and Pharmabiota but also some larger corporates, we hope to see these agreements start to close out after the summer break. Q2: You mentioned the deal pipeline, when can investors expect to see these cross the line? A2: OptiBiotix Health do have a strong deal pipeline, it’s very difficult to give accurate timelines for deals because, as I’m sure investors can appreciate, it’s a two-way negotiation and once any partners suspect you’re working to a time limit, this can give them leverage in any negotiation. You’ve just got to think of situation where you’re trying to buy and sell a car, if you’re trying to sell your car very quickly, the price changes. However, to give our investors flavour of the amount of interest in OptiBiotix Health, we’ve had large interest since Vitafoods but a number of discussions prior to Vitafoods. As a team, we review the potential news flow going forward and we estimate that there are 39 opportunities for RNS’s between August of this year and the end of year so that’s an awful lot of opportunities. Now, not all of these will turn into RNS’s, as often there are 2–3 companies looking for deals in the same territory, investors will note that our deals with Pharmabiota and HLH are non-exclusive deals so that creates opportunities for maybe 2 or 3 companies in the same territory. Generally speaking, particularly with larger corporates, they want a single territory or a single continent so it would exclude others but hopefully those sort of numbers, we’re sitting on opportunities that we’re looking at, maybe not all of them will develop but it gives investors flavour about the amount of activity taking place and the scale of the opportunity. So, there’s an awful lot going on, that in itself creates a challenge of the breadth of capability within the team, particularly over these summer months when people are on holidays but we hope to be closing out a number of deals as we exit the summer holidays. Q3: Can you tell me what all this means for OptiBiotix Health investors? A3: I think it looks very promising for investors and of course, I am probably the largest single private investor and my family have a large stake holding in the company, many of those bought at 75p and we’re below that now. So, as I said at the start of this interview, I want to reassure investors that the fluctuation in share price don’t worry me but in terms of what it means for investors, you need to look at this across the board. We’re in a really exciting space, the microbiome, we’re building not just a single product technology platform but we’re developing a number of product platforms and these are at different stages of development and I created this purposely as it spreads investor risk across a number of opportunities. Of course, those earlier platforms, the SlimBiome and the OptiScreen platform that creates the cholesterol product LPLDL, they’re now entering the commercial phase of development with the launch of Vitafoods in mid-May of this year so early stage of commercialisation. As mentioned earlier, these products have stirred up a lot of commercial interest and I think there’s a number of times now, that this is probably the greatest interest I’ve had in any product and we hope that these will come to fruition in the next few months. Investors should also note, if they look up Biopharma or Pharmabiota, these companies have a very good reputation for investing in scientifically validated products which they sell into the high-value pharmaceutical market. It’s the growing trend in both small and large companies in Pharmabiota products of this type so these are products that are natural products, that have a strong clinical evidence base and a lot of science behind them. From OptiBiotix Health’s point of view, we are establishing early sales in these pharmacies and this helps build credibility in the science and consumer acceptance as pharmaceutical products. This opens up opportunities then to larger retailers to maybe recognise the opportunity there in terms of the science behind these products and the traction in the pharmacies will then build into their sales pipelines going forward. I just hope investors can start to see the momentum building up as we create multiple partnerships across multiple territories with each partner starting to contribute small amounts but incrementally increasing to grow revenue. We see this as a very low risk, low cost approach to accessing multiple healthcare markets and pharmaceuticals markets across the world which, if we’re successful in this, we can generate 7-figure revenues in the forthcoming years. So, we can see a lot of opportunities with the early stage and that early stage development, as I touched on earlier, creates the opportunity for substantive share growth. So, initially, we we’re in early stage of scientific development and now we’re in the early stages of commercial development and there’s a lot of activity taking place which have the potential to create substantial value. Now, we hope that investors will see that and stick with us as we go forward.
15/7/2017
19:43
f3rdinand: Monkey, you keep stating that OPTI is a 'jam tomorrow' sort of share with no profits, so just wondered what companies you invest in? Genuinely interested!You see if OPTI was already turning a profit of circa 5-10 million per annum then we'd be looking at a share price in excess of £2 and not 60p! If you invest in companies already turning a profit; you're probably involved in FTSE companies where share price growth will be very slow! We are invested here for the future and believe we've found a share which WILL turn over considerable profits in the next year or so and when the ball is rolling- due to the business model- it will snowball very quickly: as will the share price!Comments suggesting OPTI have nothing special in the market are also laughable! What other company offers:1) Hunger free dieting.2) Cholesterol reducing products (with efficacy potentially as good as statins) that can also decrease blood pressure.3) Healthy sweet fibres (at a time where sugar intake is such a major political issue)Given all the above I'm very confident I've backed the right horse here and yes it's taking longer than I hoped/ initially expected, but OPTI has IP that any fool can see is going to be in extremely high demand!
22/6/2017
20:08
parob: Great post Elrico. I guess investors will try and work out the value of each deal as they come through. If you believe in SOH, the science, the strategy - the key is to get in there before official revenue guidance is offered. Hope you don't mind me posting Speccy - your mum will be pleased if you get a few more hits on the blog! hTTps://speccyinvestor.blogspot.co.uk Thursday, 22 June 2017 One last Optibiotix push Something is severely wrong with the market. I expressed disbelief that following the signing of a 3-year supply contract for LPLDL® with HLH Biopharma, the share price of OPTI:Optibiotix had dropped back below 70p. Yesterday it dropped further. It's crazy!! OPTI:Optibiotix are in contract negotiations with other potential LPLDL® suppliers after interest from 30 companies at the recent Vitafoods event. Each contract signed will be the equivalent of free money - the expenditure has been completed on the R&D and a manufacturer has been appointed - who will also be paying 50% of their proceeds to OPTI:Optibiotix. All this is just for LPLDL®, and given the news time granted to a potential cholesterol-reducing injection yesterday (not available for 5 years), the fact OPTI:Optibiotixhave something ready to market now that does exactly that, should be another signal of the potential revenues. Add to that Slimbiome sales just kicking off, promised free shares in SBTX:SkinBiotherapeutics and the launch of Sweetbiotix in late 2017 to early 2018, as well as a platform designed to discover further applications for the microbiome, and the short, medium and long term potential is just staggering. I've got a standing order for £200 a month going into a savings account. It's meant to be for emergencies or paying for holidays. I decided last night to divert it for 12 months in order to take advantage of the market insanity around OPTI:Opibiotix. I took out a 12 month loan for £2,250 paying off at just under £200 a month and cancelled my savings standing order. This will cost me £167 interest over the year. I expect to make that back within a week when the market corrects.
21/6/2017
20:42
bdog51: Whilst it's somewhat disappointing to see the OPTI share price stagnate yet again, take a look at 4D Pharma.. down from 800p to 250p in the last 8 months. I always thought 4D was overvalued, yet it didn't stop Woodford piling in big time.Meanwhile with OPT in the 60s I'm a buyer as I believe we're going to hit the big time in due course, many hot irons in the fire here. Revenue forecasts will drive the re-rate.
10/6/2017
18:53
parob: riskybusiness1 - 06 Jun 2017 - 09:09 - 24143 of 24143 - 0I wrote to walbrook over the weekend asking about ysf and how some believe they are at fault for suppressing the share price through dropping on market. Also asked for any future revenue indications. Some of it didn't actually relate to what I asked but interesting nevertheless I assume from soh:'This is an incorrect assumption as the YSF is not selling down shares in drip sales. As a regional investment fund its reason d'aitre is to support new investments and occasionally it has to sell shares to allow it to reinvest or to bid for external funds. We are fortunate that our institutional investors are very supportive of OptiBiotix and when there is a need to sell shares rather than put them on the market they will often approach us first. This allows OptiBiotix to place shares with interested institutional investors who are looking for large amounts of shares but are unlikely to buy small amounts in the market. With a large volume this is often at a market discount which temporarily affects the share price. Please note that all market sensitive information is shared with all investors and 'institutional investors' do not have access to any information which is not available in the market. I am particularly keen on this and hence I gave exactly the same presentation to retail investors at the recent evening presentation that was used for institutional investors during the day. The company does not release news to buoy the share price and doesn't get too disconcerted by the day to day volatility in share price which is largely driven by market sentiment often influenced by bloggers. We are building a £200m+ company and are progressing through the phases of creating the science, building the IP, proving the science in laboratory and clinical studies and then commercialising innovative products. If we build the company on a solid base the share price will follow and be sustained.We are at the early stage of commercialisation of two products (SlimBiome and LP-LDL) with a third product (SweetBiotix) following later this year or the start of next. I have been pleasantly surprised at the high level of interest from companies in these products and we anticipate a range of agreements following on from our launch in Vitafoods. These should start to feed through in the following weeks and months whereupon we will announce to the market. As some of these deals can be worth in the regions of £5m per annum I am sure you can see that given the multiples in this industry (10-20) even if you use the lower multiple a £200m+ valuation is within reach. Share growth and company valuation has to be based on a solid foundation and I believe the next phase of share growth will come as we gain commercial traction with our products, which based on the high level of interest and 30+ ongoing discussions, look extremely promising. Investors who attend my presentation will be aware that this is all part of a structured plan and the reason we appointed a new Commercial (Per Rehne) and Sales Director (Christina Wood) in Jan 2017. They joined us at the end of March and as planned we launched products in May. As previously announced we have extensive global interest and the next few weeks and months should see these deals closing out whereupon we will announce to the market This next 18 moths should be exciting for OptiBiotix and its shareholders and hopefully, like with the Tata deal, we can announce a few surprise deals to help build the company to the next level.I am happy for this to be circulated widely as it does not contain new market sensitive information.'elrico - 06 Jun 2017 - 18:29 - 24165 of 24167 - 6Hi Stephen,I had an exchange with HLH recently (see attached) and Bathe confirmed OPTI LP-LDL will be on the shelves mid July, costs 30 capsules -18,90 € & 90 capsules-39,90 €. They ship to UK. I had a number of people asking about these, which prompted me to enquire. Google translate was helpful 😊Would it be appropriate to OPTI to disclose margin, costs for deals like this, or would this give away too much to competitors. I suspect when revenues are acknowledge and the cost base remains flat at c£1m pa, this would be clear enough.I cannot help notice your usual conservative tone has changed to one of a more upbeat, even excited and now I learn you have ventured to use projections for some of the deals being negotiated. It was also very pleasing to learn YSF are not the sole reason for holding us in the current trading range. I have long since argued YSF have a stated exit strategy of 3-6 years and aim to do so in an orderly manner. I have also argued this will be better facilitated once OPTI are able to provide number for brokers, which will enable an even more orderly exit. As one of my friends like to say, "I am sanguine."Hi,I have worked with distributors for years and they can be very difficult/disheartening so was pleasantly surprised at Vitafoods at the high level of interest in both LP-LDL and SlimBiome and can start to see a clear path to revenues of £3-6m+ per year for each of these in the not too distant future. As many people will tell you from my presentations I explain I don’t reveal margin and costs as from experience this then sets a starting point for other deals, which then become lower. This creates a risk that each deal is less profitable than the previous.Everything is building nicely and whilst there are no guarantees this is looking very promising and I would like to be announcing a number of deals in the forthcoming weeks and months. I would also like to be able to announce our plans to return value in SBTX which is a complicated process but I believe achievable.Feel free to share as this contains no market sensitive informationBest Wishes,Stephen OHara
06/6/2017
09:09
riskybusiness1: I wrote to walbrook over the weekend asking about ysf and how some believe they are at fault for suppressing the share price through dropping on market. Also asked for any future revenue indications. Some of it didn't actually relate to what I asked but interesting nevertheless I assume from soh:'This is an incorrect assumption as the YSF is not selling down shares in drip sales. As a regional investment fund its reason d'aitre is to support new investments and occasionally it has to sell shares to allow it to reinvest or to bid for external funds. We are fortunate that our institutional investors are very supportive of OptiBiotix and when there is a need to sell shares rather than put them on the market they will often approach us first. This allows OptiBiotix to place shares with interested institutional investors who are looking for large amounts of shares but are unlikely to buy small amounts in the market. With a large volume this is often at a market discount which temporarily affects the share price. Please note that all market sensitive information is shared with all investors and 'institutional investors' do not have access to any information which is not available in the market. I am particularly keen on this and hence I gave exactly the same presentation to retail investors at the recent evening presentation that was used for institutional investors during the day. The company does not release news to buoy the share price and doesn't get too disconcerted by the day to day volatility in share price which is largely driven by market sentiment often influenced by bloggers. We are building a £200m+ company and are progressing through the phases of creating the science, building the IP, proving the science in laboratory and clinical studies and then commercialising innovative products. If we build the company on a solid base the share price will follow and be sustained. We are at the early stage of commercialisation of two products (SlimBiome and LP-LDL) with a third product (SweetBiotix) following later this year or the start of next. I have been pleasantly surprised at the high level of interest from companies in these products and we anticipate a range of agreements following on from our launch in Vitafoods. These should start to feed through in the following weeks and months whereupon we will announce to the market. As some of these deals can be worth in the regions of £5m per annum I am sure you can see that given the multiples in this industry (10-20) even if you use the lower multiple a £200m+ valuation is within reach. Share growth and company valuation has to be based on a solid foundation and I believe the next phase of share growth will come as we gain commercial traction with our products, which based on the high level of interest and 30+ ongoing discussions, look extremely promising. Investors who attend my presentation will be aware that this is all part of a structured plan and the reason we appointed a new Commercial (Per Rehne) and Sales Director (Christina Wood) in Jan 2017. They joined us at the end of March and as planned we launched products in May. As previously announced we have extensive global interest and the next few weeks and months should see these deals closing out whereupon we will announce to the market This next 18 moths should be exciting for OptiBiotix and its shareholders and hopefully, like with the Tata deal, we can announce a few surprise deals to help build the company to the next level. I am happy for this to be circulated widely as it does not contain new market sensitive information.'Ends
17/5/2017
12:29
bernieboy: Don't think we are finished for the day yet. Further rises I think and I mean Opti share price!
03/5/2017
07:38
owenmo: Yes Parob - however Opti share price and RNSs in recent times demonstrate a dysfunctional relationship. Will May 3rd. be any different? But I share your view that it's a matter of time.
28/4/2017
12:20
pglancy: somuwin, i do not mind admitting i am really confused with the sbtx shares. you say. 'It seems to me that this situation with the 'free' shares is similar to any other company that decides to distribute a special dividend. i.e Company X says that they will distribute a cash divi equal to say 10% of the value of the company on a certain date. Shareholders will then receive the cash bonus, but in most cases the company's share price will drop by a similar amount (10% in this case) immediately following.' If the total investment of opti money is 650k how can the value whatever sbtx is now be wiped off the opti share price especially when the market did not see value at the time of its investment, according to soh quote.
25/4/2017
13:05
scotty1: OptiBiotix Health PLC (LON:OPTI) Q&A with CEO Stephen O’Hara: AIM Listing of Skinbiotherapeutics PLC Posted by: Amilia Stone 25th April 2017 OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the listing of SkinBiotherapeutics PLC onto the AIM market, what this means for shareholders and how it fits in with OptiBiotix Health’s overall strategy Q1: We’ve just seen the launch of SkinBiotherapeutics PLC (LON:SBTX) separately on AIM, can you explain the rationale behind this? A1: Yes, sure. Just after listing OptiBiotix in August 2014 it became clear to me that the microbiome space was developing very rapidly and there was a window of opportunity for OptiBiotix to capitalise on our first move advantage and acquire IP in other areas in the microbiome space. There were two areas of particular interest, one was the skin microbiome and the second was the role of the microbiome in cognitive health, that is in stress, anxiety, mood etc., now, we’re still exploring opportunities in cognitive health and we’ll update shareholders if that opportunity materialises. Moving on to skin, in terms of the skin microbiome, I’ve spent 12 months identifying and accessing skin technology around the world before I finally met up with Professor Andrew McBain and Dr Catherine O’Neill in early 2015 at Manchester University. I was really impressed with Manchester University, I was impressed with their expertise, their facilities and their links to industry in particular the skin field and so I set about acquiring the rights to the technology. This took 12 months and in March 2016 we reached an agreement to acquire the IP from Manchester University for £250,000 and we set up a joint venture company called SkinBiotix Limited which OptiBiotix own 50%. However, it became clear to myself and the Board that the opportunity offered by Skin and its potential future value was not really transparent to shareholders in OptiBiotix and it’s not surprising really considering that as a young company, we’ve only been on the Stock Market for just over 2 years, we have quite a diversity of IP and quite a diversity of commercial relationships across a number of microbiome areas. There’s a reason for this, whilst this approach has complexity, it’s been designed to mitigate development risk in an evolving scientific field and provide a cost-effective way to build overlapping IP and exploit the many opportunities offered by the microbiome. So, it terms of listing Skin, the listing of SkinBiotherapeutics materialises the value of this part of the business so it’s now transparent to shareholders in OptiBiotix. OptiBiotix now owns 41.9% of a company valued and listed at £11 million which was risen over the last few days, the first few days of trading, to be £16-17 million so this means that OptiBiotix shareholders now have a significant shareholding, 42%, in an appreciating asset. More importantly, SkinBiotherapeutics has £4.5 million worth of cash to build future value in the business from these development programmes, which, similar to OptiBiotix, have targeted a very large consumer markets. So, I think it’s a great opportunity in a very exciting space. Q2: I think you’ve touched on this but what could this mean for OptiBiotix investors and is there any idea on the timing involved? A2: So, our focus really is on developing Skin and building value from these development programmes, that’s the immediate focus. As the value of SkinBiotherapeutics increases, this will of course benefit OptiBiotix, as a major shareholder, as the share price in SkinBiotherapeutics goes up, the market cap goes up, OptiBiotix as the major shareholder will benefit from that. At some point, in the not so distant future, and we have stated this time and time again but just to restate it, we want to distribute value in SkinBiotherapeutics back to OptiBiotix Health shareholders, now, this is quite a complex process, and we’re working with our advisers on the fairest way of achieving this. We can’t give exact timings on this because as I’m sure you can appreciate, this is market-sensitive information but we’ll probably link any distribution to shareholders over defined time periods for example, to shareholders who held shares continuously between two time points such as the start and end of a particular month. This overcomes the anomaly where a particular trader sells or holds a number of shares for a very short period of time and gains an undue benefit so mitigate the possibility of shareholders trading in OptiBiotix simply to gain a position in Skin, this time period will be retrospective so for example, if we were looking to distribute value in the Autumn then we’d link that to shares held over a period of time in the preceding Spring. So, just to reemphasise this is just an example, the mechanism, the timing of any distribution of value has yet to be determined and would depend very much on the SkinBiotherapeutics’ progress and market conditions. Our overall aim is to ensure the best long-term approach of building value in OptiBiotix to the benefit of all its shareholders. Q3: How does this fit in with OptiBiotix Health PLC’s overall strategy? A3: We announced this strategy back in July last year and the listing of SkinBiotherapeutics reflects a strategy to realise the growing value of each division which the Board believes is currently not being fully realised when viewed as a whole. So, typically, shareholders look at OptiBiotix Health and judge it on the basis of its products that are closer to market but as we’ve shown with Skin, which is quite early in its development, the value of that was not fully realised until we listed it on the Stock Market. This strategy allows investors in OptiBiotix to build up a broad-based investment portfolio across a number of areas in the microbiome space, which diversifies risk, whilst offering shareholders multiple opportunities in this really exciting space. As each listed company grows in value, OptiBiotix shareholders will benefit from the appreciation of each asset and this is a really exciting and innovative business model which, over time, looks to give OptiBiotix shareholders a position in multiple companies which is a prospect of multiple returns. So, it’s a good time for OptiBiotix Health shareholders and we’re determined to, mentioned at the very beginning, to build value in Skin and to turn some of that value to shareholders as time goes on.
Optibiotix H. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170820 17:30:17